Market Access News | pharmaphorum

News

Sanofi, GSK claim their first COVID jab approval

For all their long history in vaccines, GSK and Sanofi have struggled to get a shot for COVID-19 authorised – but they have finally crossed the finish line in Europe.

News

FDA panel backs AZ’s PT027 asthma rescue drug, but in adults...

AstraZeneca has moved a step closer to bringing a first-in-class drug to market in the US that can be used to reduce severe asthma attacks, after an FDA advisory committee voted in favour o

News

FDA blocks early filing for ADC drug, signalling tougher sta...

ADC Therapeutics has said it will not seek accelerated approval of its Hodgkin lymphoma drug camidanlumab tesirine (cami) based on phase 2 results, as the FDA will not review it unless a co

News

NICE backs digital CBT apps for youngsters with anxiety

Draft guidance in the UK has provisionally recommended that digital cognitive behavioural therapy (CBT) apps can be used within the NHS to treat children and young people with mild to moder

News

AZ, Sanofi get first green light for RSV prophylactic antibo...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections.<

News

Hand in glove holding Petri plate with bacteria Steptococcus Phaemolifticus G, Streptococcus Agalactiae, Streptococcus Phaemolifticus

GSK preps filing for novel antibiotic for urinary tract infe...

In an encouraging development for the fight against antimicrobial resistance (AMR), GSK's novel antibiotic gepotidacin has shown efficacy in two phase 3 trials, setting up regulatory filing

Sanofi, GSK claim their first COVID jab approval

FDA panel backs AZ’s PT027 asthma rescue drug, but in adults...

FDA blocks early filing for ADC drug, signalling tougher sta...

NICE backs digital CBT apps for youngsters with anxiety

AZ, Sanofi get first green light for RSV prophylactic antibo...

GSK preps filing for novel antibiotic for urinary tract infe...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks